Fairvalue-Calculator Fairvalue-Calculator
EN DE

SIGA Technologies, Inc (SIGA) Fair Value & Analysis

Healthcare · US · Market cap $315M

Price$4.30
Fair Value$7.15
Upside+66.3%
Quality95/100
Evidence: High Range $5.36 – $8.93

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SIGA Technologies, Inc (SIGA) currently trades at $4.30, while our model-based Fair Value estimate is $7.15 — implying the stock looks roughly 66.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is SIGA Technologies, Inc (SIGA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $7.15 versus a price of $4.30 — about +66% (undervalued). Model-based estimate, not financial advice.
What is the fair value of SIGA?
Our 21-model fair value for SIGA Technologies, Inc is $7.15 (as of Jun 24, 2026), built from audited fundamentals. The current price is $4.30.
What is the quality score of SIGA?
SIGA Technologies, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.